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httpType II endoleaks after endovascular repair of
abdominal aortic aneurysm are not always a benign
condition
Salma El Batti, MD,a Frédéric Cochennec, MD,a Françoise Roudot-Thoraval, MD,b and
Jean-Pierre Becquemin, MD,a Créteil, France
Objective: The aim of the study was to determine whether type II endoleak (T2E) after endovascular repair of abdominal
aorta (EVAR) is a benign condition (ie, not associated with growth, reintervention, rupture, or death).
Methods: Data from patients who underwent EVAR for atherosclerotic infrarenal aortic aneurysms between June 1995
and May 2010 in the Vascular Surgery Department of Henri Mondor Hospital were prospectively collected. Data from
patients presenting with at least one T2E on computed tomography scan during their follow-up were compared with
those with no T2E. Three subcategories of T2E were studied according to time of occurrence (early or late), persistence
(persistent or transient), and recurrence (recurrent or not recurrent).
Results: Seven hundred patients were included with follow-up ranging from 1 month to 15 years (median, 31.3 months;
range, 12.4-61.4); 201 (28.9%) had at least one T2E. Patients with T2Es were signiﬁcantly older (P < .001), female (P[
.015), had larger aneurysms (P [ .019), and patent lumbar arteries (P [ .003). Patients without T2Es had a higher
incidence of current smoking (P < .001) and chronic obstructive pulmonary disease (P < .005). Multivariate analysis
showed risk of T2E was increased in older patients (odds ratio [OR], 1.04; conﬁdence interval [CI], 95% 1.02-1.06; P <
.001) and in those with patent lumbar arteries (OR, 1.70; CI, 95% 1.16-2.50; P [ .007), and was reduced in active
smokers (OR, 0.16 CI, 95% 0.04-0.71; P[ .015) or patients with coronary artery disease (OR, 0.65; CI, 95% 0.45-0.92;
P [ .016). Patients with T2Es had more complications (death, rupture, reintervention, or conversion) (P < .001) and
greater aneurysm sac enlargement (>5 mm upon follow-up) (P < .001). Multivariate analysis showed T2E was a risk
factor for aneurysm diameter growth >5 mm; this risk was increased if T2E persisted more than 6 months (hazard ratio
[HR], 3.16; CI, 95% 2.55-6.03; P < .001), was recurrent (HR, 1.88; CI, 95% 1.18-3.01; P [ .008), or associated with
a type I or III endoleak (HR, 1.96; CI, 95% 1.41-2.73; P < .001). Recurrent T2E was associated with a higher rate of
reintervention (P [ .04) and conversion to open surgery (P [ .028).
Conclusions: Not all T2Es are benign. Recurrent as well as persistent T2Es are prone to life-threatening complications.
(J Vasc Surg 2013;57:1291-8.)First reported by Parodi in 1991,1 endovascular repair EVAR in the United States, and showed that endovascular
of abdominal aortic aneurysms (EVAR) has become
a viable alternative to conventional surgical repair because
of reduced postoperative mortality rates.2,3 However,
four randomized studies have shown that EVAR carries
a signiﬁcant complication rate including reintervention,
conversion to open repair, or even rupture. Furthermore,
these studies have failed to prove the superiority of
EVAR on long-term mortality.4-7
Endoleaks account for 60% of complications after EVAR
and are responsible for more than 45% of all reinterven-
tions.2 Schanzer reviewed pre- and postoperative computed
tomography (CT) scans of 10,228 patients who underwentthe Department of Vascular Surgerya and Department of Public
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://dx.doi.org/10.1016/j.jvs.2012.10.118repair failed to prevent aneurysm enlargement in 41% after
5 years,8 the main risk factor being the existence of endoleak
of any type (hazard ratio [HR], 2.7).
Although type I or type III endoleaks could be consid-
ered as a failure of endovascular repair to exclude the aneu-
rysm, type II endoleaks (T2Es) have been considered by
some as a benign complication.9,10 However, this has
been questioned by others who reported increasing aneu-
rysm diameters and rupture in patients with T2Es.11-13
Not all T2Es seem equivalent. Persistent T2Es have
been reported to lead to aneurysm sac expansion or
rupture, although data from the European Collaborators
on Stent Graft Techniques for Abdominal Aortic Aneurysm
Repair (EUROSTAR) registry failed to show a signiﬁcant
association.14-16 T2E management is still debated. Some
studies suggest the safety of a conservative approach,
even with increasing aneurysm diameter,17,18 whereas
others advocate intervention if aneurysm enlargement
occurs or if T2E does not resolve within 6 months.
The aim of this article, based on the 15-year experience
of a single institution, is to determine whether T2E is
a benign condition, (ie, not associated with growth, rein-
tervention, rupture, or death) and to optimize postopera-
tive surveillance and management thereby preventing
endovascular treatment failure.1291
Table I. Demographic variables of patients with or without T2E
T2E No T2E
P valuen % n %
Patients 201 499
Age, years (mean 6 SD) 75.4 6 8.1 71.6 6 9.0 <.001
Male sex 182 90.5 476 95.4 .015
Follow-up, months (median) 36.7 26.1 .004
Diabetes 24 11.9 64 12.8 .750
Hypertension 105 52.2 286 57.3 .220
CAD 66 32.8 214 42.9 .015
Chronic renal insufﬁciency 29 14.4 66 13.2 .680
COPD 45 22.4 168 33.7 .005
Hypercholesterolemia 102 50.7 174 34.9 <.001
Tobacco use 57 28.4 280 56.1 <.001
ASA Score
ASA1 5 2.5 10 2.0
.870ASA2 85 42.3 198 39.7
ASA3 105 52.2 275 55.1
ASA4 6 3.0 16 3.2
Aneurysm anatomy
Aorto iliac 194 96.5 472 94.6 .280
Aortic 7 3.5 27 5.4
AAA size, mm (mean 6 SD) 56.2 6 8.9 54.5 6 8.3 .019
Thrombus position 154 76.6 410 82.2
.180Anterior 37 18.4 70 14.0Posterior 25 12.4 75 15.0
Circumferential 92 45.8 265 53.1
Lumbar arteries’ patency 153 76.1 322 64.5 .003
ASA, American Society of Anesthesiology; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation; T2E, type II
endoleak.
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We reviewed all patients who underwent EVAR for
atherosclerotic infrarenal aortic or aortoiliac aneurysms
between June 1995 and May 2010 at the Department of
Vascular Surgery, Henri Mondor Hospital, Creteil, France.
Patients with ruptured, anastomotic, inﬂammatory, or
infectious aneurysms were excluded. Patients with less
than 1-month follow-up were also excluded due to lack of
ﬁrst surveillance CT scan (standard at 1 month in our
institution).
Retrospective analysis of data from a prospectively
maintained speciﬁc database (Logical Interference Tester
[LOGIT]) was performed. Preoperative, intraoperative, and
follow-up data were collected. A senior surgeon assessed
eligibility for EVAR and stent graft device choice after
completion of a contrast-enhanced CT scan.
According to the French Agency for Sanitary Security
of Health Products recommendations, patients underwent
clinical examination, abdominal X-ray, abdominal aortic
duplex ultrasound, and contrast-enhanced CT scan with
millimetric cuts and delayed phase images within the ﬁrst
month after EVAR, at 6 months, and yearly thereafter. A
senior surgeon and radiologist assessed the presence of
any endoleak and maximum aneurysm diameter. Decisions
regarding reintervention and time to next examination
were left to the surgeon’s choice.
Patients’ clinical and procedural characteristics and
follow-up data were collected prospectively. All variableswere deﬁned according to the deﬁnitions of the American
Society for Vascular Surgery. The patency of lumbar arteries
was assessed on preoperative CT.
Patients included were divided into two groups accord-
ing to presence or absence of T2E on follow-up. Patients
that presented with T2Es at the postprocedural completion
arteriography but not on any CT scan performed after the
ﬁrst month were included in the group without T2Es. In
the T2E group, three subcategories were deﬁned according
to T2E evolution proﬁle. T2Ewas considered as early or late
depending on onset before or after ﬁrst postoperative
month; T2Es were named transient or persistent relating
to resolution or not after 6 months; and recurrent T2E
was deﬁned as the occurrence of a new T2E, from the
same origin, independent of the resolution of the ﬁrst
T2E, and regardless of delay between the two.
Postoperative complications such as death, rupture,
aneurysm sac enlargement >5 mm within 6 months, rein-
terventions for any reason other than T2E, reinterventions
for T2Es, endovascular conversion, and conversion to
open were collected.
Statistical analysis. Continuous variables were ex-
pressed as mean 6 1 SD or median (ﬁrst to third quartile)
according to their distribution and were analyzed by
a Student t-test or by the Mann-Whitney U test for
unpaired comparisons. Qualitative variables were analyzed
with a c2 test or Fisher test where appropriate. Survival
and postoperative event curves were estimated by the
Table II. Procedure details of patients with or without
T2Es
T2E No T2E
P valuen % n %
Procedure performed
before 2000
86 42.8 198 39.7 .450
Stent graft type
Aorto uniiliac 31 15.4 52 10.4
.220
Bifurcated 165 82.1 425 85.2
Tube 1 0.5 7 1.4
Branched 0 0 0 0
Fenestrated 4 2 15 3
N/A 2 1 7 1.4
.160
AneuRxa 6 3.0 12 2.4
Cook Zenithb 131 65.2 345 69.1
EVTc 6 3 7 1.4
Gore Excluderd 25 12.4 37 7.4
Stenforde 4 2 6 1.2
Stentorf 3 1.5 4 0.8
Medtronic Talentg 8 4 36 7.2
Vanguardh 14 7 42 8.4
Vascutek Anacondai 2 1 3 0.6
Prior lumbar arteries
embolization
7 3.5 10 2 .280
Internal iliac artery 41 20.4 83 16.6 .240
Embolization 29 14.4 52 10.4 .140
Coverage 36 17.9 65 13.0 .100
Inferior mesenteric
artery embolization
1 0.5 5 1.0 .680
Aortic extension 5 2.5 9 1.8 .560
Iliac extension 24 11.9 66 13.2 .630
T2E, Type II endoleak.
aMedtronic, Santa Rosa, Calif.
bCook Medical, Bloomington, Ind.
cGuidant, Indianapolis, Ind.
dW. L. Gore & Associates, Flagstaff, Ariz.
eStenford Groupe Valendos S.A., Nanterre, France.
fMinTec, La Ciotat, France.
gMedtronic Vascular, Minneapolis, Minn.
hBoston Scientiﬁc, Natick, Mass.
iVascutek, Inchinnan, Scotland, UK.
Table III. Multivariate analysis of the inﬂuence of
preoperative variables on the occurrence of T2E
Variables OR 95% CI P value
Age 1.04 1.02-1.06 <.001
Tobacco use 0.16 0.04-0.71 .015
Lumbar arteries patency 1.70 1.16-2.50 .007
Coronary artery disease 0.65 0.45-0.92 .016
CI, Conﬁdence interval; OR, odds ratio; T2E, type II endoleak.
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signiﬁcance by log-rank test.
A multivariate analysis was performed by selecting vari-
ables found to be signiﬁcantly associated with the presence
of a T2E in the univariate analysis, using a logistical regres-
sion model. This model determined odds ratios and conﬁ-
dence intervals (CIs). A Cox regression hazard model was
used for multivariate analysis of the incidence of aneurysm
sac enlargement in each group. This model determined
HRs and CIs. Differences were considered as signiﬁcant
if P value #.05.
All statistical analyses were performed using SPSS v.18
(SPSS, Inc, Chicago, Ill) and Stata v.11 (StataCorp,
College Station, Tex) software.
RESULTS
During the 15-year inclusion period, 754 patients un-
derwent elective endovascular repair of an infrarenal aortic
or aortoiliac aneurysm. Fifty-four patients without ﬁrst
month surveillance CT scan were excluded. Two hundred
one patients had at least one T2E at follow-up (28.7%)
and 499 patients did not develop a T2E (71.3%). Mean
patient follow-up was 31.3 months (12.4-61.4).
Preoperative patient demographics and anatomic vari-
ables are summarized in Table I. Preoperative variables
associated with the occurrence of a T2E were female sex
(P ¼ .015), older age (P < .001), and hyperlipidemia
(P < .001). The presence of coronary disease (P ¼
.015), chronic obstructive pulmonary disease (COPD)
(P ¼ .005), and tobacco use (P < .001) were signiﬁcantly
higher in the group without T2Es. Preoperative large
aneurysm diameter (P ¼ .019) and lumbar artery patency
(P ¼ .003) were statistically associated with T2Es. When
stratifying patients with aneurysms over 55 mm according
to the ranges (55-60 mm, 60-70 mm, over 70 mm), the
difference was statistically signiﬁcant in patients with
aneurysms over 70 mm (23 T2Es [11.4%] vs 32 (6.4%]
no T2Es; P < .03). We found no other signiﬁcant differ-
ence in anatomic variables and in thrombus topography
between patients with or without T2Es. Furthermore,
no statistically signiﬁcant difference was found according
to graft design (ie, bifurcated vs aorto uniiliac) or to the
various devices used (Table II). Pre-emptive embolization
of lumbar arteries (17 patients) or of the inferior mesen-
teric arteries (six patients), left to surgeon’s choice, had
no signiﬁcant inﬂuence on the onset of T2Es (seven
T2Es vs 10 without T2Es after lumbar artery emboliza-
tion, P < .5; one T2E vs ﬁve without T2Es after inferior
mesenteric artery embolization, P < .52).
During follow-up, there was no signiﬁcant difference in
the occurrence of type I or type III endoleaks between the
two groups (T2E: 24.4% vs no T2E: 26.7%; P ¼ .8), and
the median onset of type I and III endoleaks in the T2E
group was 11.9 months vs 12.8 months in the group
without T2Es.
Multivariate analysis (Table III) showed risk of T2E
occurrence was higher when lumbar arteries were patent
and with increasing age (4% increase per year of age). Onthe contrary, T2Es were less frequent in patients with coro-
nary artery disease and persisting tobacco use.
Kaplan-Meier analysis showed no inﬂuence of T2E on
survival (Fig 1). All-cause mortality was 24.4% in the T2E
group and 24.3% in the group without T2Es (P ¼ 1).
Median survival was 106 months and 108 months, respec-
tively (P ¼ .49).
Fig 1. Kaplan-Meier analysis of survival with or without type II
endoleak (T2E) shows no statistical difference (P ¼ .49).
Table IV. Outcomes on patients with or without T2E
T2E No T2E
P valuen % n %
All complications 92 45.8 118 23.6
Rupture 4 2 5 1 .290
Conversion to open 12 6 18 3.6 .210
Endovascular conversion 7a 3.5a 10 2 .280
Aneurysm sac enlargement 81 40.3 84 16.8 <.001
Reinterventionb 30 14.9 33 6.6 .002
T2E, Type II endoleak.
aIn cases of association of type I and/or III endoleak.
bExcept for speciﬁc treatment of T2E.
Fig 2. Kaplan-Meier analysis of complications with or without
type II endoleak (T2E).
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observed in 81 patients (40.3%) with T2Es compared
with 84 (16.8%) patients without T2Es (P < .001). In
the T2E group, 40 patients (19.9%) underwent speciﬁc
treatment of the T2E.
Speciﬁc treatment of T2Es included 31 coil emboliza-
tions and nine surgical ligations of inferior mesenteric
and/or of lumbar arteries. The embolization procedure
closed the T2E and stopped the aneurysm sac enlargement
in only seven cases (22%).
Among the 41 patients that did not undergo speciﬁc
treatment for T2E, 19 had an isolated transient T2E at
the time of the increase in diameter; thus, there was no
speciﬁc target to treat. Four of these 19 patients had
a recurrent endoleak. The remaining 22 patients had
a type of endoleak associated with a type I or III endoleak
and underwent reinterventions and conversions (16 rein-
terventions, four conversions to open, one endovascular
conversion, and one rupture treated by endovascular
conversion).
In the T2E group, 30 patients (14.9%) underwent rein-
tervention for any other reason compared with 33 (6.6%)
in the no T2E group (P ¼ .002). Conversions to open
were indicated when aneurysm sac enlargement could not
be stopped by an endovascular treatment of a T2E or
a type I or type III endoleak or for rupture. There was
no signiﬁcant inﬂuence of the presence of a T2E on
conversion to open repair or rupture (Table IV). As shown
in Fig 2, Kaplan-Meier analysis showed a signiﬁcant differ-
ence in complications between the two groups (P < .001)
with increased complications when T2Es were present.
Univariate analysis of variables associated with adverse
outcomes in patients with T2Es (Table V) showed that
persistent T2Es (68% vs 32.5%; P < .001) and anterior
thrombus (P ¼ .015) were associated with aneurysm sac
enlargement. Recurrent T2Es were associated with a higher
rate of reintervention (P ¼ .001), of conversion to open
repair (P < .001), and of aneurysm sac enlargement(P < .001). The combination of a T2E with a type I or
III endoleak was associated with a higher rate of reinter-
vention (P < .001).
Kaplan-Meier analysis of the inﬂuence of subcategor-
ies of T2E on outcome is shown in Fig 3, A-C. Late and
persistent T2Es were associated with aneurysm sac enlarge-
ment (P ¼ .015 and P < .001, respectively). Recurrent
T2Es were associated with aneurysm sac enlargement (P ¼
.001), with a higher rate of reintervention (P ¼ .004), and
of conversion to open repair (P ¼ .028).
Multivariate analysis showed that T2E was an indepen-
dent predictor of aneurysm sac enlargement (Table VI)
but not of rupture. Persistent T2Es (HR, 3.16; 95%
CI, 2.55-6.03; P < .001), recurrent T2Es (HR, 1.88;
95% CI, 1.18-3.01; P ¼ .008) and association with
a type I or a type III endoleaks (HR, 1.96; 95% CI,
1.41-2.73; P < .001) were highly predictive of sac growth.DISCUSSION
This study demonstrates that T2E jeopardizes the
durability of EVAR. The presence of T2E is associated
with aneurysm sac enlargement; importantly, we have
shown that not all T2Es are equivalent and that persistent
Table V. Univariate analysis of variables associated with adverse outcomes
Variable Death Rupture Reintervention Open conversion Endovascular conversion Sac enlargement
Anterior thrombus .015
No lumbar arteries patent .04 .015 .036
Prior lumbar arteries embolization .04
Persistent T2E <.001
Recurrent T2E .001 <.001 <.001
T2E þ T1E or T3E .053 <.001
T1E, Type I endoleak; T2E, type II endoleak; T3E, type III endoleak.
Table VI. Multivariate analysis of independent
predictors of aneurysm sac enlargement
Variable HR 95% CI P value
No T2E 1
Persistent T2E 3.16 2.55-6.03 <.001
Recurrent T2E 1.88 1.18-3.01 .008
T2E associated
with T1E or T3E
1.96 1.41-2.73 <.001
CI, Conﬁdence interval; HR, hazard ratio; T1E, type I endoleak; T2E, type
II endoleak; T3E, type III endoleak.
Fig 3. Type II endoleak (T2E) and aneurysm sac enlargement,
Kaplan-Meier analysis and log-rank test. A, Late vs early T2Es. B,
Persistent vs transient T2Es. C, Recurrent vs nonrecurrent T2Es.
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secondary interventions (excluding speciﬁc treatment of
T2E) was increased in the T2E group. Speciﬁc treatment
of T2Es did not prevent occurrence of new endoleaks
and aneurysm sac enlargement.
This study reviews data from a 15-year experience of
EVAR; we included patients treated with ﬁrst generation
stent grafts because we found no difference in incidence
of T2Es in literature reviews. In addition, there was no
change in incidence of T2Es in our population before or
after the year 2000.
In this report, 28.7% of patients presented with at least
one T2E during follow-up. Previous studies have shown an
incidence of T2E varying from 7.8% to 25%,2,11,14-16,18-22
with various deﬁnitions. Some authors have only recorded
early T2Es that were present within the ﬁrst postoperative
month and others have recorded those that persisted after
the ﬁrst month, whereas late T2Es are seldom recorded. In
our study, we recorded any T2E, regardless of time of
diagnosis and duration; associations were made between
the various subcategories of T2E and their clinical
outcomes.
Demographic and anatomic variables associated with
T2Es have been reported in previously published series.
Among them, past medical history, age, absence of
peripheral arterial disease, and anticoagulation therapy
were found to be frequently associated with T2E.15,23,24
Anatomic variables associated with T2Es were a longer
proximal neck, a larger AAA diameter, inferior mesenteric
artery preoperative patency, and the number of patent
lumbar arteries.14,16,20,23,24 Our ﬁndings conﬁrm some of
these: age, lumbar arteries patency, absence of COPD, and
absence of coronary artery disease. Multivariate analysis
Table VII. Literature review of incidence and outcomes of T2E
Authors Year n
Follow-up,
months
T2E Persistent T2E Sac enlargement T2E reintervention Open conversion Rupture
No. (%)
Timaran11 2004 348 26.5 32 (9.2) 32 (100) 13 (40.6) 16 (50) 0 (0) 1 (3.1)
Jones15 2007 873 32.6 164 (18.8) 33 (20.1) 40 (24.4) 16 (9.8) 3 (1.8) 4 (2.4)
Abularrage16 2010 595 34.8 136 (22.8) 89 (65.4) 73 (53.7) 39 (28.7) 1 (0.7) 2 (1.5)
Rayt17 2009 369 50.4 39 (10.5) 25 (64.1) 6 (15.4) 1 (2.6) 0 (0) 0 (0)
Steinmetz18 2004 486 21.7 90 (18.5) 35 (38.9) 5 (5.6) 5 (5.6) 0 (0) 0 (0)
Sylverberg21 2006 965 22 154 (15.9) N/A 13 (8.4) 19 (12.3) 0 (0) 0 (0)
AbuRahma22 2011 266 22.1 56 (21) 15 (26.8) 5 (8.9) 4 (7.1) 0 (0) 0 (0)
Van Marrewijk24 2003 3595 15 320 (9) N/A 71 (22.2) N/A 5 (1.6) 1 (0.3)
Our study 2011 700 31.3 201 (28.7) 44 (21.9) 81 (40.3) 40 (19.9) 12 (6) 4 (2)
T2E, Type II endoleak.
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protective, as suggested by reports of the EUROSTAR
registry.21,23,24 Explanation of these ﬁndings is not clear
but we may hypothesize that a higher intra-abdominal
pressure and blood viscosity alterations in patients with
COPD, favoring spontaneous thrombosis of low-pressure
endoleaks, may explain this fact. Tobacco use can cause
COPD and induce atherosclerotic injury of medium- and
small-size vessels, such as leg arteries or coronary arteries.
Among anatomic variables studied, only a larger aneurysm
diameter was found to be associated with T2Es. Thrombus
topography, position, thickness,16 and nidus size,11
although previously described as predictors, had no
signiﬁcant inﬂuence on the occurrence of T2Es in univari-
ate analysis. However, multivariate analysis showed that
an anterior position was associated with aneurysm sac
enlargement.
Sheehan’s report of 1909 patients in ﬁve centers, with
a homogenous distribution of various devices20 showed
a relationship between device used and occurrence of
T2E. In this study, most cases were treated with Cook
Zenith (Cook Medical, Bloomington, Ind) bifurcated
devices. This may have biased the statistical results, and
we did not ﬁnd any inﬂuence of the device on T2E.
Management of T2E is still debated since clinical
outcomes vary in published literature (Table VII). Some
did not report major complications related to T2E such
as rupture, conversion to open, and related death.17,18,21
Thus, most authors do not advocate systematic treatment
of T2Es, unlike type I or III endoleaks. Indeed, conversion
to open and rupture are mainly associated with type I and
III endoleaks,9,10,14 which bring back a high pressure
blood ﬂow to the atrophic aneurysm wall.9,14,25,26
The inclusion of type I and type III endoleaks in our
study could be considered as a confounding factor, but as
there was no signiﬁcant difference in the occurrence of
type I or type III endoleaks between the two groups
(T2E: 24.4% vs no T2E: 26.7%; P ¼ .8), we decided
not to exclude them from our two groups to better
appreciate their interactions. Furthermore, multivariate
analysis suggests that T2E is an independent predictor of
aneurysm sac enlargement, even if association of T2Ewith a type I or III endoleak increases the risk of aneurysm
sac enlargement.
Dias has reported various deﬁnitions of T2E according
to hemodynamic data from duplex ultrasound.26 The ratio
between measured pressure in the aneurysm sac and
systemic pressure in patients with T2Es ranges from 22%
to 92%. This ﬁnding can explain the various outcomes of
T2E, ranging from spontaneous resolution and sac
shrinkage to sac enlargement and even rupture.
Persistent T2Es have been reported as predictors of
aneurysm sac enlargement, conversion to open, and
rupture.15 Evolution patterns seem to be determinant in
T2E outcomes. In our study, T2Es persisted in 44% of
patients with T2Es. This ratio varies in the literature:
20.1% in Jones’s series, and 38% in Steinmetz’s.15,18 Jones
only recorded all T2Es present within the ﬁrst month,
thus missing later T2Es. In our study, persistence of T2E
was associated with aneurysm sac enlargement and although
speciﬁc treatment of T2E was performed in case of sac
enlargement with persistent T2E, it could not prevent
occurrence of new endoleaks and aneurysm sac enlargement
in cases of transient and recurrent endoleaks.
We deﬁned recurrent T2E as the occurrence of a new
T2E, from the same origin, independent of the resolution
of the ﬁrst T2E, and regardless of the delay between the
two. In our series, 71% of recurrent endoleaks have led to
aneurysm sac enlargement (P < .001), an independent
predictor by multivariate analysis. Although further studies
are warranted, these data could modify the algorithm
of T2E management by a more aggressive attitude with
earlier sac embolization in selected cases of persistent or
recurrent T2Es.
Although a recent meta-analysis27 did not ﬁnd any
adequate information to support any one threshold for
intervention, sac enlargement is an indication for correc-
tion of T2E for most authors. However, there is still no
consensus about the best therapy, although a recent report
28 suggested that Onyx embolization performed as the
ﬁrst secondary intervention was associated with a higher
success rate. Whether signiﬁcant sac enlargement is signif-
icantly related to increased mortality and rupture is still
debated.29
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Volume 57, Number 5 El Batti et al 1297Based on the ﬁndings of our study, our current algo-
rithm for T2E is as follows: (1) if the aneurysm enlarges,
we intervene to treat the endoleak; and (2) if the size of
the sac remains stable and T2E does not resolve, we repeat
the CT scan (or duplex) every 6 months, then yearly
thereafter.
CONCLUSIONS
Not all T2Es are benign. Transient and early T2Es lead
to less adverse outcomes, whereas recurrent as well as
persistent T2Es lead to aneurysm sac enlargement and
life-threatening complications. These should be closely
monitored to ensure early and speciﬁc treatment.
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